Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• This progress reflects the strength of our data, the safety demonstrated during the Loder clinical trial, the urgency of the unmet need in pancreatic cancer, and our continued execution toward developing a potentially transformative therapy

  60% confidence

• The Phase 2a clinical trial of Loder showed a positive trend in comparison to the control of chemotherapy alone

  60% confidence

• KRAS mutations are present in over 90% of pancreatic cancers

  60% confidence

• Silexion plans to advance SIL204 as a potential treatment across additional KRAS-driven indications, including colorectal and lung cancers

  60% confidence

• We are now advancing SIL204 into a pivotal clinical trial with the goal of addressing KRAS-driven cancers at their source

  60% confidence

• SIL204 demonstrated significant anti-tumor activity in multiple preclinical models

  60% confidence

• The receipt of this approval marks a defining and highly significant milestone for Silexion

  60% confidence

• The Company expects to initiate the Phase 2/3 trial in the second quarter of 2026, subject to site activation and standard clinical readiness procedures

  60% confidence

Cited in these Via News reports

• Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD →
• China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →